Zhongguo Fei Ai Za Zhi = Chinese Journal of Lung Cancer

Our medical research library holds 12 studies published in Zhongguo Fei Ai Za Zhi = Chinese Journal of Lung Cancer (2010–2026). Each entry links to the study's record on PubMed and, where there is one, to the publisher's page and a free full text. 11 have an abstract, the authors' own summary as PubMed records it: open "Abstract" to read it.

About the journal

• Publisher: Zhongguo fei ai za zhi bian ji wei yuan hui
• Published: 1998 to the present, China
• Language: Chinese, English
• ISSN: 1009-3419 (print), 1999-6187 (electronic)
• Its record in the NLM Catalog

2020s

• [Ileal Perforation Caused by Pleural Mesothelioma-related Small Intestinal Involvement: A Case Report and Literature Review]. Y. Wang, F. Shen, Q. Li, et al. 2026;29(6):462-468. In Chinese. Case report · Review PubMed · Publisher · Free full text

  Abstract

  Pleural mesothelioma (PM) usually manifests as local intrathoracic invasion, and small intestinal involvement is rare. A 37-year-old man with initially diagnosed stage IV diffuse PM and no definite history of asbestos exposure or other specific occupational or environmental exposure except for long-term smoking was reported. After first-line treatment with Pemetrexed, Carboplatin and Bevacizumab, the disease remained stable. However, acute abdomen occurred during maintenance therapy, and emergency surgery confirmed terminal ileal perforation. Postoperative pathology suggested PM-related ileal involvement/metastatic involvement, with a higher Ki-67 proliferation index than that of the primary lesion. Because only perforation repair rather than segmental bowel resection was performed, the available pathological material could not determine whether full-thickness bowel-wall involvement was present or the direction of tumor invasion. Imaging findings, intraoperative findings and pathological results did not support primary peritoneal mesothelioma or direct contiguous invasion of the ileum by the diaphragmatic lesion; however, microscopic peritoneal dissemination with secondary bowel-wall involvement could not be completely excluded. The aim of this report, together with literature review, is to summarize the diagnostic challenges, management strategies and clinical implications of PM-related small intestinal involvement. .

• [Pleural Well-differentiated Papillary Mesothelial Tumor Presenting with Recurrent Pneumothorax and Pleural Effusion: A Case Report]. Z. Li, F. Kong, B. Yang, et al. 2026;29(5):390-394. In Chinese. Case report · Review PubMed · Publisher · Free full text

  Abstract

  Well-differentiated papillary mesothelial tumor (WDPMT) is a rare neoplasm characterized by a distinct papillary architecture, bland cytological features, and a propensity for superficial spread without stromal invasion. We herein report the diagnosis and management of a patient with pleural WDPMT presenting predominantly with recurrent spontaneous pneumothorax and pleural effusion, along with a review of the current literature on this entity. The patient was a 58-year-old female who presented with a two-week history of chest tightness and dyspnea on a background of recurrent spontaneous pneumothorax and pleural effusion over the preceding seven years. She had experienced four episodes of recurrence during that period and denied any history of asbestos exposure. Thoracoscopic exploration revealed pulmonary bullae, pleural effusion and pneumothorax, pleural thickening, and scattered grayish-white nodules on both the visceral and parietal pleura. Histopathological examination of the pleural nodule biopsy confirmed the diagnosis of WDPMT. Based on the features of this case and a review of the literature, clinicians should be aware that WDPMT may present with the atypical manifestation of recurrent spontaneous pneumothorax accompanied by pleural effusion. .

• [Recent Advances in Medical Treatment of Malignant Pleural Mesothelioma]. J. Yang, F. Kong. 2025;28(5):391-399. In Chinese. Review PubMed · Publisher · Free full text

  Abstract

  Malignant pleural mesothelioma (MPM) is a highly aggressive malignancy originating from mesothelial cells of the pleura, primarily associated with asbestos exposure, and is often characterized by poor prognosis. Due to the lack of specific clinical manifestations in the early stages, the diagnosis of MPM presents a significant challenge, leading to most patients being diagnosed at an advanced stage, which limits the effectiveness of surgical treatment. Consequently, systemic therapies are commonly required. Although Pemetrexed in combination with Platinum-based chemotherapy remains the first-line standard treatment for unresectable MPM, its therapeutic efficacy is limited, and more effective treatment strategies are urgently needed. In recent years, immune checkpoint inhibitors have made significant progress in the treatment of MPM, markedly improving patient survival outcomes. With the increasing depth of molecular biological research on MPM, targeted therapies offer promising personalized treatment options. Additionally, the therapeutic potential of novel strategies such as cell therapy and oncolytic virus therapy is beginning to emerge. This review summarizes the latest advancements in the medical treatment of MPM and looks forward to future therapeutic directions, aiming to provide insights for clinical practice. .

• [Advances in Targeted Therapy for Malignant Pleural Mesothelioma]. F. Fu, Y. Zhang, H. Shen. 2024;27(5):391-398. In Chinese. Review PubMed · Publisher · Free full text

  Abstract

  Malignant pleural mesothelioma (MPM) is a rare cancer with high malignancy and aggressiveness on the pleural, caused by the following risk factors including asbestos inhalation, genetic factors, and genetic mutation. The present chemotherapy, antiangiogenic therapy, and immunotherapy methods are ineffective and the survival time of patients is very short. There is an urgent need to find potential therapeutic targets for MPM. At present, it has been found the following types of targets: gene mutation targets such as BRCA associated protein 1 (BAP1) and cyclin-dependent kinase 2A (CDKN2A); epigenetic targets such as lysine (K)-specific demethylase 4A (KDM4A) and lysine-specific demethylase 1 (LSD1), and signal protein targets such as glucose-regulated protein 78 (GRP78) and signal transducer and activator of transcription 3 (STAT3). So far, available clinical trials include phase II clinical trials of histone methyltransferase inhibitor Tazemetostat, poly (ADP-ribose) polymerase (PARP) inhibitor Rucaparib and cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitor Abemaciclib, as well as phase I clinical trials of mesothelin-targeting chimeric antigen receptor T-cell immunotherapy (CAR-T) cell injection in the thoracic cavity and TEA domain family member (TEAD) inhibitor VT3989 and IK-930, and the results of these trials have showed certain clinical efficacy. .

• [Advances in Immunotherapy for Malignant Pleural Mesothelioma]. Y. Chi, Y. Liu, J. Zhao. 2022;25(4):259-265. In Chinese. PubMed · Publisher · Free full text

  Abstract

  Patients with malignant pleural mesothelioma (MPM) usually present with poor prognosis and short survival period, and there has been a lack of effective treatment options for a long time. Chemotherapy has limited improvement in the clinical outcome of advanced patients (the median survival is less than one year), and it is difficult to find suitable targets for targeted therapy. Recent in-depth research on immunotherapy has changed the treatment pattern of MPM. Especially, the dual immunotherapy regimen significantly improved the survival outcome of patients across subgroups and prolonged the survival time of MPM patients. Therefore, it has been approved for unresectable MPM as first-line treatment for patients. The exploration of other mono or combo immunotherapy regimens in the first and second-line settings of MPM is also underway. How to identify the best beneficial population of each regimen through predictive biomarkers is also a hot spot for researchers. This article will focus on the most up-to-date progress of MPM epidemiology, histological characteristics, pathogenesis, treatment patterns and the advances of immunotherapy in the disease. .

• [Analysis of the Efficacy of Pemetrexed Maintenance Therapy in Patients with Malignant Pleural Mesothelioma]. X. Zeng, Z. Jiang, J. Duan. 2022;25(1):7-13. In Chinese. PubMed · Publisher · Free full text

  Abstract

  Background: Malignant pleural mesothelioma (MPM) is a highly aggressive disease arising from pleural mesothelial cells. Advanced pleural mesothelioma has a poor prognosis, with a median survival of no more than 15 months. First line standard chemotherapy regimen recommended is Pemetrexed based chemotherapy regimen, with or without bevacizumab. There is no consensus on whether patients who have received first-line standard chemotherapy can benefit from pemetrexed maintenance chemotherapy. The study aimed to investigate the efficacy and safety of pemetrexed maintenance therapy (PMT) after treatment with a pemetrexed and platinum regimen for patients with MPM.

  Methods: A total of 40 MPM patients were collected from Cancer Hospital Chinese Academy of Medical Sciences from January 2013 to January 2018, eligible patients were unresectable MPM, without disease progression following 4 to 6 cycles of pemetrexed and platinum, including pemetrexed maintenance therapy group (22 cases) and observation group (18 cases). The last follow-up was conducted in January 2020. The primary endpoint were progression free survival (PFS), and the secondary end points were overall survival (OS), the efficacy, adverse reactions of PMT.

  Results: The median PFS in the PMT arm was longer than that in the observation arm (8.5 mon vs 3 mon, P=0.008), but there was no significant difference in median OS (26.4 mon vs 15.7 mon, P=0.177). Objective response rate (ORR) of two group were 22.7% and 0%, respectively. The grade 3-4 toxicity in PMT group included grade 4 neutropenia in 1 patient (4.5%), grade 3 neutropenia in 1 patient (4.5%), grade 4 anemia in 1 patient (4.5%) and grade 3 nausea and anorexia in 1 patient (4.5%).

  Conclusions: Pemetrexed maintenance therapy following initial pemetrexed and platinum chemotherapy improve PFS in patients with MPM, and is well tolerated.

• [Multivariate Analysis of Solid Pulmonary Nodules Smaller than 1 cm in Distinguishing Lung Cancer from Intrapulmonary Lymph Nodes]. J. Tang, C. Liu, P. Wang, et al. 2021;24(2):94-98. In Chinese. PubMed · Publisher · Free full text

  Abstract

  Background: Preoperative diagnosis and differential diagnosis of small solid pulmonary nodules are very difficult. Computed tomography (CT), as a common method for lung cancer screening, is widely used in clinical practice. The aim of this study was to analyze the clinical data of patients with malignant pulmonary nodules and intrapulmonary lymph nodes in the clinical diagnosis and treatment of <1 cm solid pulmonary nodules, so as to provide reference for the differentiation of the two.

  Methods: Patients with solid pulmonary nodules who underwent surgery from June 2017 to June 2020 were analyzed retrospectively. The clinical data of 145 nodules (lung adenocarcinoma 60, lung carcinoid 2, malignant mesothelioma 1, sarcomatoid carcinoma 1, lymph node 81) were collected and finally divided into two groups: lung adenocarcinoma and intrapulmonary lymph nodes, and their clinical data were statistically analyzed. According to the results of univariate analysis (χ² test, t test), the variables with statistical differences were selected and included in Logistic regression multivariate analysis. The predictive variables were determined and the receiver operating characteristic (ROC) curve was drawn to get the area under the curve (AUC) value of the area under the curve.

  Results: Logistic regression analysis showed that the longest diameter, Max CT value, lobulation sign and spiculation sign were important indicators for distinguishing lung adenocarcinoma from intrapulmonary lymph nodes, and the risk ratios were 106.645 (95%CI: 3.828-2,971.220, P<0.01), 0.980 (95%CI: 0.969-0.991, P<0.01), 3.550 (95%CI: 1.299-9.701, P=0.01), 3.618 (95%CI: 1.288-10.163, P=0.02). According to the results of Logistic regression analysis, the prediction model is determined, the ROC curve is drawn, and the AUC value under the curve is calculated to be 0.877 (95%CI: 0.821-0.933, P<0.01).

  Conclusions: For <1 cm solid pulmonary nodules, among many factors, the longest diameter, Max CT value, lobulation sign and spiculation sign are more important in distinguishing malignant pulmonary nodules from intrapulmonary lymph nodes.

• [Research Progress of Immune Checkpoint Inhibitors in Malignant Pleural Mesothelioma]. Y. Huang, Q. Meng. 2021;24(6):441-446. In Chinese. Review PubMed · Publisher · Free full text

  Abstract

  Malignant pleural mesothelioma (MPM) is a malignant tumor with strong invasiveness, low survival rate and lack of effective treatment options. As the only first-line treatment plan for the advanced MPM, combination of pemetrexed and cisplatin chemotherapy have been existing since the last 20 years. Immunotherapy has long been considered as a potential treatment plan for MPM, mainly including immune checkpoint inhibitors (ICIs), immunotoxin therapy, anti-cancer vaccine and adoptive T-cell therapy. This review focuses on summarizing the current research status of immune checkpoint inhibitors in MPM, discusses the effect of tumor heterogeneity on ICIs treatment, and describes that the biomarker-oriented immunotherapy is a new vision for the realization of individualized treatment of MPM. .

2010s

• [Clinical analysis of 45 patients with malignant pleural mesothelioma]. J. Chen, W. Zhao, X. Liu, et al. 2012;15(2):97-102. In Chinese. PubMed · Publisher · Free full text

  Abstract

  Background And Objective: Malignant pleural mesothelioma (MPM) is a rare tumor with increasing incidence, and its early diagnoses and early treatments are difficult. The aim of the current study is to investigate the clinical features, diagnoses, and treatments of MPM, and provide reference for clinical use.

  Methods: A total of 45 MPM patients admitted in the Chinese PLA General Hospital from January 1997 to December 2010 and their clinical records were analyzed retrospectively.

  Results: The major clinical symptoms of the patients included: chest pain (53.33%), chest distress (48.89%) and cough (37.78%). The CT manifestations of MPM included: pleural thickening (71.11%), pleural effusion (60%) and lung shadow (40%). The pleural fluid was exudative. The number of nucleated cells in the fluid increased, most of which were mononuclear cells. Moreover, the lactic acid dehydrogenase (LDH) levels in the culture medium significantly increased. The most common clinical stage of MPM patients was either stage of III or IV. Thoracoscopy was one of the main diagnosis methods, and epithelium cell type was the main pathologic type. In addition, MPM was easily misdiagnosed as tuberculous pleurisy. Patients with an early stage of MPM were mainly cured through surgery, whereas chemotherapy was applied for the patients with advance stage. The disease control rate of the patients with epithelial type was higher than that of the patients with fibrosarcoma type.

  Conclusions: The rate of MPM misdiagnosis is high because most of the patients have untypical clinical symptoms. However, CT scan can provide an important basis for the diagnosis of MPM. The accurate diagnoses were based on pathological examinations and immunohistochemistry. The methods of treatment include chemotherapy, surgical operation, radiotherapy and supportive treatment. However, these treatments are still insufficient and require further studies.

• [A cross-sectional investigation on risk factors of lung cancer for residents over 40 years old in Chengdu, Sichuan Province, China]. B. Chen, W. Li, Y. Jia, et al. 2010;13(11):1021-6. In Chinese. PubMed · Publisher · Free full text

  Abstract

  Background: In the previous studies, we have designed the Self-evaluation Scoring Questionnaire for High-risk Individuals of Lung Cancer. In order to make a better understanding of the status of risk factors of lung cancer for residents in Chengdu, we carried out the investigation from June 2009 to December 2009.

  Methods: With the stratified random sampling method, eligible residents were included and their risk factors of lung cancer were collected with the Self-evaluation Scoring Questionnaire for High-risk Individuals of Lung Cancer.

  Results: According to the criteria of the questionnaire, 21.34% of the population were at high risk of lung cancer. The smoking rate for male was 48.58%, higher than that of 2.65% for female. About 5.39% of male smokers began smoking before 15 years old. The average daily tobacco consumption in the most population was less than 20 pieces, with a duration between 20 to 40 years. However, there were 11.34% of all women suffered from passive smoking, and another 15.30% and 5.86% of residents were exposed to cooking fumes, minerals or asbestos. As for the previous illness history, 0.77%-18.08% of individuals have connective tissue diseases, pulmonary tuberculosis, emphysema and others. Finally, 4.91% of residents endured the long-term mental depression, and 7.24% had a positive family history of tumors.

  Conclusions: The status of risk factors for lung cancer among residents in Chengdu was not optimistic. It should be paid more attention to tobacco control and environmental improvement to improve people's health.

• [Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma]. A. Scherpereel, P. Astoul, P. Baas, et al. 2010;13(10):C23-45. In Chinese. Guideline PubMed · Publisher · Free full text

• Analysis of the effect of radiotherapy on malignant pleural mesothelioma when given on adjuvant or palliative basis. H.A. El Hossieny, F. Aboulkasem, M. Abdel Rahman. 2010;13(1):54-9. PubMed · Publisher · Free full text

  Abstract

  Background And Objective: This retrospective study was designed to evaluate the response and survival of malignant pleural mesothelioma to radiotherapy when delivered with surgery and chemotherapy and when delivered alone or with chemotherapy.

  Methods: A study for 110 patients with malignant pleural mesothelioma who presented to radiotherapy department, National Cancer Institute, Cairo and received radiation therapy in the period fromJanuary 1999 to July 2007.

  Results: Forty-six patients (41.8%) received trimodality therapy (surgery & adjuvant or neoadjuvant chemotherapy & adjuvant radiotherapy), while bimodality therapy (chemotherapy & radiotherapy) in 38 patients (34.5%), while 26 patients (23.6%) received single modality therapy (palliative radiotherapy), 22 patients (20%) developed local recurrence, 22 patients (20%) developed distant metastases months, 14 patients (12.7%) developed local disease progression, 25 patients (22.7%) are still alive and free of disease at time of reporting. The median survival for all patients was 16 months, while 12 and 18 months overall survival were 63.6% & 31.8% respectively while median survival for stage II, III, IV patients was 16.5, 12.5 and 8 months respectively.

  Conclusion: Multimodality approach involving surgery, chemotherapy and radiotherapy have been evaluated and proved its superiority in improving survival, especially in stages II.

Browse every journal in the library or the library by type of article, or return to medical research.